Loading
ESR2 (Oestrogen receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer and Prostate cancer.
Nuclear hormone receptor. Binds oestrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing oestrogen response elements (ERE) in an oestrogen-dependent manner. Lacks ligand binding ability and has no or only very low ERE binding activity resulting in the loss of ligand-dependent transactivation ability.
CIViC holds 7 clinical evidence items and 0 assertions across 3 variants, naming Tamoxifen and Exemestane. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes clinical 0.98, affected pathway 0.61, literature 1.00, genetic association 0.54, animal model 0.51).
In plain words · ESR2 (Oestrogen receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer and Prostate cancer.
ESR2 (Oestrogen receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer and Prostate cancer.
Nuclear hormone receptor. Binds oestrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing oestrogen response elements (ERE) in an oestrogen-dependent manner.
No product in this corpus aims at ESR2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ESR2: RNA tissue enhanced (adrenal gland 7 nTPM, ovary 6 nTPM, testis 6 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Prostate cancer); Open Targets associates it with 1 specific cancer type at or above 0.5 (breast cancer). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas ESR2 tissue; Open Targets ENSG00000140009 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Mosselman et al, FEBS Lett, 1996, "ER beta: identification and characterization of a novel human estrogen receptor". Source.
Sources: HGNC HGNC:3468 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q92731 (protein name, function text, keywords and locations (REST API)); CIViC gene ESR2 (7 evidence items, 0 assertions, 3 variants; diseases: Breast Cancer, Prostate Cancer (GraphQL API, CC0)); Open Targets ENSG00000140009 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: breast cancer 0.62 (GraphQL API, CC0))
Nuclear hormone receptor. Binds oestrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing oestrogen response elements (ERE) in an oestrogen-dependent manner. Lacks ligand binding ability and has no or only very low ERE binding activity resulting in the loss of ligand-dependent transactivation ability. Location: Nucleus (UniProt). Locus 14q23.2-q23.3 (HGNC).
RNA: tissue enhanced (adrenal gland 7 nTPM, ovary 6 nTPM, testis 6 nTPM), detected in many normal tissues.
No normal tissue stained high; medium in Adrenal gland.
No cancer stained high; medium in cervical cancer, colorectal cancer.
HPA ESR2 tissue · HPA ESR2 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ESR2" OR ABSTRACT:"ESR2" OR TITLE:"estrogen receptor 2" OR ABSTRACT:"estrogen receptor 2" OR TITLE:"Estrogen receptor beta" OR ABSTRACT:"Estrogen receptor beta" OR TITLE:"NR3A2" OR ABSTRACT:"NR3A2" OR TITLE:"Erb" OR ABSTRACT:"Erb" OR TITLE:"ER-beta" OR ABSTRACT:"ER-beta") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ESR2, not a curated reading list.